Please assess the completion status of the following clinical trial:

Trial Title: Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subjects with type 2 diabetes diagnosed during the past 2 years,~* above 18 years of age,~* drug naive, or have been on metformin less than 3 months~Exclusion Criteria:~* subjects with type 1 diabetes or GAD positive subjects or subjects with long standing diabetes (\>2 years) or subjects who are not drug naive or have been on metformin more than 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Triple Therapy (Type: EXPERIMENTAL): initiation a combination of metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) at the time diabetes is diagnosed
- conventional therapy (Type: ACTIVE_COMPARATOR): sequential addition of metformin, glyburide and basal insulin

Based on this trial design, predict the completion outcome and termination type (if applicable).